Hypervision Surgical
Hypervision Surgical is a spin-out company formed from King’s College London and was founded by a team of clinicians, medical imaging and AI experts. They have developed an AI-powered computational hyperspectral imaging system to differentiate tumour from healthy tissue reliably. This provides surgeons with intelligent vision and can drive robotic systems to improve surgical precision and patient safety during surgery.
Scroll down for our interview with the founder:
Interview with:
Michael Ebner, CEO & Founder
Why did you start Hypervision Surgical?
As part of our research at King’s College London we performed the first in-patient studies with our prototype system. In order to develop our technology further for the patient and public benefit, the idea was born to spin-out Hypervision Surgical and make this a reality.
What has been your happiest moment so far as a startup founder?
To see the team grow and throw their all behind developing this promising technology, which recently culminated in our tech being used to guide an in-vivo surgery. I am immensely proud to work with such a fantastic team.
What is the most important thing you’ve learned to date?
Things worth having don’t come easy.
Are there any founders or companies you look up to?
I look up to those successful entrepreneurs who stay grounded and help the next generation follow suit.
Which words or phrases do you most overuse?
Currently, ‘fundraising’.
What is the quality you most admire in a colleague?
Integrity.
What is your current state of mind?
Proud of the team, optimistic for the future, and ready for the next steps. There is so much to be done before we can make a difference in patient outcomes.
What has your experience been like so far as a spin out venture?
Building a medical device company for surgery is hard work, but also an exhilarating and immensely gratifying experience, especially with the right team. It’s very humbling to see Hypervision Surgical mature as we transition from prototype to medical device development stages, including the use of our system during clinical trials. Without our mentors and advisors and the highly supportive environment, all this would not have been possible.
Why did you decide to partner with KHP Ventures?
The King’s MedTech ecosystem represents a unique environment that combines the excellence of a globally-leading university in medical technology and two respected NHS hospital trusts. As a spin-out company formed from King’s College London, Hypervision Surgical has the opportunity to generate patient impact with a technology that was born in and continues to be developed in this unique environment.
Looking to the future, what do you hope Hypervision Surgical will achieve?
By providing real-time actionable information during surgery, we want to create direct value at a global scale for 1) the patient through better outcomes and fewer repeat surgeries, 2) healthcare providers by reducing follow-up treatment costs and increasing operational efficiency and 3) OEMs, such as robotics or navigation companies, by guiding their systems to deliver high-precision surgery for patients.